Literature DB >> 1279952

Control of angiogenesis by heparin and other sulfated polysaccharides.

J Folkman1, Y Shing.   

Abstract

Heparin and its related polysaccharides are revealed to have important new functions as regulators of blood vessel growth and regression. This regulatory activity may be explained in part by at least five mechanisms in which heparin and heparan sulfate interact with peptide growth factors: (1) Heparin and heparan sulfate have a high affinity for angiogenic growth factors such as the fibroblast growth factors and VEGF, as well as for angiogenic inhibitors such as thrombospondin and platelet factor 4. (2) Heparin and its related polysaccharides stabilize bFGF and other growth factors. (3) FGFs and thrombospondin are stored in the extracellular matrix bound to heparan sulfate; fragments of heparin or heparan sulfate may act as natural chaperones to shuttle bFGF or other growth factors to different cellular compartments. (5) Heparin-like low-affinity receptors on the surface of endothelial cells (and other cells), prepare FGFs for binding to their specific high affinity receptors; and (6) Heparin and its related polysaccharides potentiate angiostatic steroids. It is likely that future investigations will uncover even more fundamental regulatory roles for heparin as well as for other polysaccharides in the normal function of growth factors, especially in the complex process of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279952     DOI: 10.1007/978-1-4899-2444-5_34

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  50 in total

Review 1.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.

Authors:  I Vlodavsky; Y Friedmann
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds.

Authors:  Janet E Reing; Bryan N Brown; Kerry A Daly; John M Freund; Thomas W Gilbert; Susan X Hsiong; Alexander Huber; Karen E Kullas; Stephen Tottey; Matthew T Wolf; Stephen F Badylak
Journal:  Biomaterials       Date:  2010-08-21       Impact factor: 12.479

Review 4.  Prevention of pelvic radiation disease.

Authors:  Lorenzo Fuccio; Leonardo Frazzoni; Alessandra Guido
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-02-06

Review 5.  Inhibition of fibroblast growth factors.

Authors:  A Wellstein; F Czubayko
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Management of severe burn injuries with topical heparin: the first evidence-based study in Ghana.

Authors:  Pius Agbenorku; Setri Fugar; Joseph Akpaloo; Paa E Hoyte-Williams; Zainab Alhassan; Fareeda Agyei
Journal:  Int J Burns Trauma       Date:  2013-01-24

7.  Low-molecular-weight heparin (LMWH)-loaded large porous PEG-PLGA particles for the treatment of asthma.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-11-28       Impact factor: 2.849

8.  Platelet-derived growth factor BB induces functional vascular anastomoses in vivo.

Authors:  D M Brown; S P Hong; C L Farrell; G F Pierce; R K Khouri
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

9.  Nucleolin: acharan sulfate-binding protein on the surface of cancer cells.

Authors:  Eun Ji Joo; Gerdy B ten Dam; Toin H van Kuppevelt; Toshihiko Toida; Robert J Linhardt; Yeong Shik Kim
Journal:  Glycobiology       Date:  2004-08-25       Impact factor: 4.313

Review 10.  Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor.

Authors:  I Vlodavsky; H Q Miao; B Medalion; P Danagher; D Ron
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.